Overcoming resistance in prostate cancer with targeted and small molecule-based therapies
- 3 November 2023
- book chapter
- Published by Elsevier
- p. 255-287
Abstract
No abstract availableKeywords
This publication has 106 references indexed in Scilit:
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor through Virtual Screening.Journal of Medicinal Chemistry, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established targetThe Lancet Oncology, 2009
- Non-competitive androgen receptor inhibition in vitro and in vivoProceedings of the National Academy of Sciences, 2009
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletionNature Reviews Endocrinology, 2009
- Tubulin-Interactive Natural Products as Anticancer AgentsJournal of Natural Products, 2009
- Mitotic catastrophe and apoptosis induced by docetaxel in hormone‐refractory prostate cancer cellsJournal of Cellular Physiology, 2008
- Role of poly(ADP-ribose) formation in DNA repairNature, 1992